FDA Approves RCC Drug, Prostate Cancer and Smoking Link: April News Roundup

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD

PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

High levels of long-lasting, multifunctional HPV16-specific CD8-positive T cells induced by PDS0101 promoted durable patient survival.

Beyond the Tumor: Addressing Body Image in Oncology

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with front-line recurrent or metastatic head and neck squamous cell carcinoma.

Daniel C. McFarland, DO;Michelle Fingeret, PhD

August 18th 2025

APPs Bridging Science and Care: Understanding and Advocating for Bispecifics in Later Line Multiple Myeloma

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Atezolizumab Plus Chemo Safe, Efficacious in Broader ES-SCLC Population

Univariate and multivariate analyses found that increased mortality was associated with the presence of liver metastases at baseline

August 24th 2025

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.

Related Content

Ariana Pelosci

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD

PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

Beyond the Tumor: Addressing Body Image in Oncology

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with front-line recurrent or metastatic head and neck squamous cell carcinoma.

Daniel C. McFarland, DO;Michelle Fingeret, PhD

August 18th 2025

APPs Bridging Science and Care: Understanding and Advocating for Bispecifics in Later Line Multiple Myeloma

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Atezolizumab Plus Chemo Safe, Efficacious in Broader ES-SCLC Population

August 24th 2025